In Q4 2024 GWP amounted to MNOK 2,688, up 30% (27% in LCY) relative to Q4 2023. UK makes up 82% of total growth in GWP this quarter. To subscribe to Press releases from this issuer, visit the ...

1,182,931 shares in Hafnia at an average price of NOK 59.6782 per share through Castel AS, which is controlled by Erik Bartnes. For more information see the attached mandatory notification of trade.

LACROIX announces the sale of its City-Mobility segment to the SWARCO group, in the wake of the exclusive negotiations between the two companies announced on December 12. This operation should be ...

*Gross Management AS' number of shares post purchase corrected. ABL Group ASA (the Company) has been notified of the following transactions by primary insider and observer of the Board of Directors, ...

Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today provided financial and business highlights for the fourth quarter of 2024 for Nicox SA and its ...

07:00 CET (1:00 a.m. ET). In connection with the earnings release, a live video webcast will be held at 15:00 CET (9:00 a.m. ET) on the same day. In order to attend, use the following submit questions ...

a subscription price per New Share of NOK 1.00 (the "Offer Price"). The net proceeds from the Private Placement will be used to fund the Company's operations, and for general corporate purposes.

Bureau Veritas, a global leader in Testing, Inspection, and Certification services, announced that it has signed an agreement to acquire Contec AQS and its two owned subsidiaries Exenet and PMPI. The ...

2024 Revenue: €31.07M (-15.5%) Continued strategic investments and customer diversification Positive momentum initiated for 2025 Egide Group (Euronext Growth Paris™- ISIN: FR0000072373 - Mnémo: ALGID) ...

Odyssée Technologies est un acteur industriel français spécialisé dans la mécanique de précision. Fort de ses savoir-faire d’excellence au travers de ses 175 salariés répartis sur trois unités de ...

POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic ...

company's uplisting to Oslo Børs and public retail offering of shares. CEO Lars-Henrik Røren and Group CFO Marius Magelie will hold a webcast to present the company on Wednesday January 22, 2025, at ...